Brief: Cocrystal Pharma Reports Q3 Financial Results, Provides Updates On Its Antiviral Development Programs
14/11/2022 18:06
Nov 14 (Reuters) - Cocrystal Pharma Inc COCP.O :
* COCRYSTAL PHARMA REPORTS THIRD QUARTER 2022 FINANCIAL
RESULTS
AND PROVIDES UPDATES ON ITS ANTIVIRAL DEVELOPMENT PROGRAMS
* COCRYSTAL PHARMA INC - QTRLY LOSS PER SHARE $0.70
Source text for Eikon: ID:nGNX5TTXxJ
Further company coverage: COCP.O
Recent news on Cocrystal Pharma
See all newsBrief: Cocrystal Pharma Announces Last Subject Dosed In Phase 1b Human Challenge Study Evaluating CDI-988 For Norovirus Prevention And Treatment
Cocrystal Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Cocrystal Pharma Inc expected to post a loss of 16 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Medtronic, Macy's, USA Rare Earth
U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway